- Home
- CARS vs IMTX Comparison
CARS vs IMTX Comparison
Compare CARS & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARS
- IMTX
- Stock Information
- Founded
- CARS 1998
- IMTX N/A
- Country
- CARS United States
- IMTX Germany
- Employees
- CARS N/A
- IMTX N/A
- Industry
- CARS Motor Vehicles
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CARS Consumer Discretionary
- IMTX Health Care
- Exchange
- CARS Nasdaq
- IMTX Nasdaq
- Market Cap
- CARS 703.7M
- IMTX 579.8M
- IPO Year
- CARS 2017
- IMTX N/A
- Fundamental
- Price
- CARS $12.06
- IMTX $5.38
- Analyst Decision
- CARS Buy
- IMTX Strong Buy
- Analyst Count
- CARS 5
- IMTX 4
- Target Price
- CARS $18.30
- IMTX $14.67
- AVG Volume (30 Days)
- CARS 890.4K
- IMTX 867.1K
- Earning Date
- CARS 08-07-2025
- IMTX 08-12-2025
- Dividend Yield
- CARS N/A
- IMTX N/A
- EPS Growth
- CARS N/A
- IMTX N/A
- EPS
- CARS 0.69
- IMTX N/A
- Revenue
- CARS $718,000,000.00
- IMTX $155,801,989.00
- Revenue This Year
- CARS $2.68
- IMTX N/A
- Revenue Next Year
- CARS $3.71
- IMTX $1.92
- P/E Ratio
- CARS $17.47
- IMTX N/A
- Revenue Growth
- CARS 2.24
- IMTX 93.56
- 52 Week Low
- CARS $9.56
- IMTX $3.30
- 52 Week High
- CARS $21.24
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- CARS 56.70
- IMTX 45.66
- Support Level
- CARS $11.01
- IMTX $5.29
- Resistance Level
- CARS $12.21
- IMTX $5.71
- Average True Range (ATR)
- CARS 0.37
- IMTX 0.31
- MACD
- CARS 0.16
- IMTX -0.10
- Stochastic Oscillator
- CARS 60.61
- IMTX 13.04
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.